We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
To begin to standardize PET scanning techniques to detect the spread of breast cancer to the lymph nodes, researchers at the Saul and Joyce Brandman Breast Center at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center have developed objective criteria that can be used to complement clinical observations.
Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has received notification of U.S. Patent Office approval for technology to which Corgenix and strategic partner Creative Clinical Concepts (CCC) hold exclusive worldwide licensing rights.
US biomedical firm Avery Biomedical Devices announced the formation of its subsidiary specialising in the manufacture of platinum devices for the medical and biomedical industries.
A new imaging procedure could reduce the risk of esophageal injury to patients undergoing heart surgery to treat atrial fibrillation, the Heart Rhythm Society (HRS) announced Aug. 22, citing a recent study.
The Centers for Medicare & Medicaid Services (CMS) Aug. 21 posted charge and payment information for 61 common procedures performed in ambulatory surgery centers (ASCs).
Device firms can save a lot of money and trouble by using an engineering technique to identify product risks during the design phase, experts said in an Aug. 16 FDAnews audioconference titled "Medical Device Failure Analysis During the Design Process."
3i Infotech, a global provider of information technology solutions, announced that BioniCare has completed the implementation of 3i Infotech's ORION(TM) CMS.
Affymetrix Inc. announced in a press release that District Court Judge Joseph J. Farnan of the United States District Court for the District of Delaware issued a Markman order in the litigation brought by Affymetrix against Illumina.
Celera Genomics, an Applera Corporation business, announced that the National Institutes of Health (NIH) has awarded Celera approximately $900,000 to develop and commercialize an in vitro diagnostic (IVD) test for the highly pathogenic influenza A/H5 virus (Asian lineage, H5N1).
Gentris Corporation (Gentris), a leading global provider of applied clinical pharmacogenomic services and diagnostic product solutions, announced the company has partnered with FALCO biosystems Ltd. (FALCO), one of the largest publicly-traded medical testing laboratories in Japan.